IL193212A0 - Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii - Google Patents
Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viiiInfo
- Publication number
- IL193212A0 IL193212A0 IL193212A IL19321208A IL193212A0 IL 193212 A0 IL193212 A0 IL 193212A0 IL 193212 A IL193212 A IL 193212A IL 19321208 A IL19321208 A IL 19321208A IL 193212 A0 IL193212 A0 IL 193212A0
- Authority
- IL
- Israel
- Prior art keywords
- tyr
- ser
- thr
- asn
- ala
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 3
- 102000001690 Factor VIII Human genes 0.000 abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 2
- 230000002439 hemostatic effect Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Monoclonal anti-idiotypic antibodies (Ab) directed against a human antibody (Ab2) that inhibits factor VIII (F8), where Ab2 is directed against the C1 domain of F8 is new. In Ab (i) at least one complementarity-determining region (CDR) of each light chain includes a peptide sequence at least 70% identical with SEQ ID NOs: 12, 13 or 14 and (ii) at least one CDR of each heavy chain includes a peptide sequence at least 70% identical with SEQ ID NOs: 9, 10 or 11. Arg-Ala-(Ser) 3-Val-Ser-Tyr-Met-Asn (12) Ala-Thr-Ser-Asn-Leu-Ala-Ser (13) Gln-Gln-Trp-Ser-Ser-Asn-Pro-Pro-Met-Leu-Thr (14) Gly-Tyr-Thr-Phe-Thr-Thr-Tyr-Trp-Met-His (9) Tyr-Ile-Asn-Pro-Thr-Ser-Gly-Tyr-Thr-Glu-Tyr-Asn-Gln-Asn-Phe-Lys (10) Ser-Gly-Ala-Tyr-Tyr-Arg-Tyr-Asp-Asp-Ala-Met-Asp-Ser (11). Independent claims are included for the following: (1) stable cell lines that produce Ab; (2) hybridoma 18D6 (CNCM I-3559); and (3) DNA fragments Seq. (15) and (16) (of 325 and 367 bp; reproduced) that encode the variable regions of, respectively, the heavy and light chains of Ab. ACTIVITY : Hemostatic. No details of tests for hemostatic activity are given. MECHANISM OF ACTION : Inhibition of autoantibodies that inactivate factor VIII.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0601633A FR2897868B1 (en) | 2006-02-24 | 2006-02-24 | ANTI-IDIOTYPIC ANTIBODIES THAT NEUTRALIZE THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST FIELD C1 OF FACTOR VIII. |
| PCT/FR2007/000342 WO2007096536A1 (en) | 2006-02-24 | 2007-02-26 | Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL193212A0 true IL193212A0 (en) | 2009-02-11 |
Family
ID=37106244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL193212A IL193212A0 (en) | 2006-02-24 | 2008-08-03 | Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080160015A1 (en) |
| EP (3) | EP2447284A1 (en) |
| JP (1) | JP2009528285A (en) |
| KR (1) | KR20080106289A (en) |
| CN (1) | CN101522718A (en) |
| AT (1) | ATE530579T1 (en) |
| AU (1) | AU2007217218A1 (en) |
| BR (1) | BRPI0707031A2 (en) |
| CA (1) | CA2643565A1 (en) |
| DK (1) | DK1996626T3 (en) |
| ES (1) | ES2376489T3 (en) |
| FR (1) | FR2897868B1 (en) |
| IL (1) | IL193212A0 (en) |
| PL (1) | PL1996626T3 (en) |
| WO (1) | WO2007096536A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2889534B1 (en) * | 2005-08-04 | 2012-11-02 | Lab Francais Du Fractionnement | ANTI-IDIOTYPIC ANTIBODY THAT NEUTRALIZES THE INHIBITORY ACTIVITY OF A FACTOR VIII INHIBITOR ANTIBODY |
| WO2009024653A1 (en) * | 2007-08-23 | 2009-02-26 | Lfb Biotechnologies | Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
| FR2933496B1 (en) * | 2008-07-02 | 2012-10-05 | Lfb Biotechnologies | METHOD OF MEASURING ACTIVE FACTOR VII RATE IN A SAMPLE |
| WO2011028229A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
| FR2969761A1 (en) * | 2010-12-22 | 2012-06-29 | Lfb Biotechnologies | METHOD OF ASSAYING ANTIBODIES DIRECTED AGAINST FACTOR VIII |
| CA2864904C (en) | 2012-02-15 | 2023-04-25 | Amunix Operating Inc. | Factor viii compositions and methods of making and using same |
| EP3549953A1 (en) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| CA2889170C (en) | 2012-10-25 | 2021-09-07 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| CN116063483A (en) | 2012-11-02 | 2023-05-05 | 美国比奥维拉迪维股份有限公司 | Anti-complement C1s antibodies and uses thereof |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| ES2938359T3 (en) | 2015-04-06 | 2023-04-10 | Bioverativ Usa Inc | Humanized anti-C1s antibodies and methods of using them |
| WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
| SG11201903012RA (en) * | 2016-10-12 | 2019-05-30 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR508320A (en) | 1920-01-12 | 1920-10-07 | Deynoux Freres | Clasp for bags and the like |
| WO2001004269A1 (en) * | 1999-07-14 | 2001-01-18 | D. Collen Research Foundation Vzw | Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
| WO2005016455A2 (en) * | 2003-08-14 | 2005-02-24 | D. Collen Research Foundation Vzw | Antibodies against factor viii with modified glycosylation in the variable region |
| EP1388544A1 (en) * | 2002-07-31 | 2004-02-11 | D. Collen Research Foundation vzw | Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof |
| FR2889534B1 (en) | 2005-08-04 | 2012-11-02 | Lab Francais Du Fractionnement | ANTI-IDIOTYPIC ANTIBODY THAT NEUTRALIZES THE INHIBITORY ACTIVITY OF A FACTOR VIII INHIBITOR ANTIBODY |
-
2006
- 2006-02-24 FR FR0601633A patent/FR2897868B1/en not_active Expired - Fee Related
-
2007
- 2007-02-26 DK DK07731046.4T patent/DK1996626T3/en active
- 2007-02-26 EP EP11186600A patent/EP2447284A1/en not_active Withdrawn
- 2007-02-26 US US11/817,018 patent/US20080160015A1/en not_active Abandoned
- 2007-02-26 CA CA002643565A patent/CA2643565A1/en not_active Abandoned
- 2007-02-26 CN CNA2007800136052A patent/CN101522718A/en active Pending
- 2007-02-26 AU AU2007217218A patent/AU2007217218A1/en not_active Abandoned
- 2007-02-26 ES ES07731046T patent/ES2376489T3/en active Active
- 2007-02-26 KR KR1020087023279A patent/KR20080106289A/en not_active Application Discontinuation
- 2007-02-26 BR BRPI0707031-4A patent/BRPI0707031A2/en not_active Application Discontinuation
- 2007-02-26 JP JP2008555845A patent/JP2009528285A/en active Pending
- 2007-02-26 EP EP07731046A patent/EP1996626B1/en not_active Not-in-force
- 2007-02-26 WO PCT/FR2007/000342 patent/WO2007096536A1/en active Application Filing
- 2007-02-26 EP EP09002329A patent/EP2100903A3/en not_active Withdrawn
- 2007-02-26 AT AT07731046T patent/ATE530579T1/en active
- 2007-02-26 PL PL07731046T patent/PL1996626T3/en unknown
- 2007-08-23 US US11/844,331 patent/US8110190B2/en not_active Expired - Fee Related
-
2008
- 2008-08-03 IL IL193212A patent/IL193212A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007096536A1 (en) | 2007-08-30 |
| FR2897868B1 (en) | 2012-08-31 |
| EP1996626A1 (en) | 2008-12-03 |
| PL1996626T3 (en) | 2012-04-30 |
| AU2007217218A1 (en) | 2007-08-30 |
| EP1996626B1 (en) | 2011-10-26 |
| ATE530579T1 (en) | 2011-11-15 |
| EP2100903A3 (en) | 2010-01-20 |
| US20090263380A1 (en) | 2009-10-22 |
| JP2009528285A (en) | 2009-08-06 |
| US20080160015A1 (en) | 2008-07-03 |
| EP2447284A1 (en) | 2012-05-02 |
| CA2643565A1 (en) | 2007-08-30 |
| BRPI0707031A2 (en) | 2011-04-12 |
| FR2897868A1 (en) | 2007-08-31 |
| ES2376489T3 (en) | 2012-03-14 |
| DK1996626T3 (en) | 2012-02-13 |
| EP2100903A2 (en) | 2009-09-16 |
| KR20080106289A (en) | 2008-12-04 |
| US8110190B2 (en) | 2012-02-07 |
| CN101522718A (en) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL193212A0 (en) | Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii | |
| PL1749537T3 (en) | Anti-idiotypics antibodies having a neutralising activity against factor VIII inhibitor antibody | |
| LT2005099A (en) | Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof | |
| TW200716182A (en) | Antibodies directed to CD20 and uses thereof | |
| TW200637873A (en) | Antibodies against interleukin-1 beta | |
| TW200716677A (en) | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders | |
| MX2007007484A (en) | Antibodies directed to angiopoietin-2 and uses thereof. | |
| FR17C1062I1 (en) | ||
| NO20063569L (en) | M-CSF-specific monoclonal antibody and its use | |
| RS80704A (en) | ANTI- av?6.ANTIBODIES | |
| SG155883A1 (en) | Anti-cd3 antibodies and methods of use thereof | |
| WO2008112004A3 (en) | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF | |
| EP1578799B8 (en) | Antibodies directed to tumor necrosis factor and uses thereof | |
| SG151284A1 (en) | Antibodies against ccr5 and uses thereof | |
| WO2003105782A3 (en) | Specificity grafting of a murine antibody onto a human framework | |
| MXPA05005925A (en) | Antibodies directed to phospholipase a2 and uses thereof. | |
| WO2006052591A3 (en) | Anti-properdin antibodies, and methods for making and using same | |
| WO2007120693A3 (en) | Targeted binding agents directed to upar and uses thereof | |
| TW200621802A (en) | Fully human monoclonal antibodies to IL-13 | |
| WO1998050433A3 (en) | Human monoclonal antibodies to epidermal growth factor receptor | |
| NZ621103A (en) | Humanized anti-factor d antibodies and uses thereof | |
| NZ584838A (en) | Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof | |
| NZ599683A (en) | Anti-ilt7 antibody | |
| WO2003057857A3 (en) | Antibodies directed to pdgfd and uses thereof | |
| RU2011140509A (en) | HETERODIMERIC POLYPEPTIDES IL-17A / F AND POSSIBILITIES OF THEIR THERAPEUTIC USE |